Patent ID: 8476023
Filing Date: 2013-07-02
Classification: C12Q,G01N,Y10T

Abstract:
1. A method for aiding in determining therapeutic efficacy of exesmestane in a subject who has or is at risk of having a condition or disease for which inhibition of aromatase is desirable to decrease estrogen in the subject, comprising: assaying a biological sample obtained from the subject for a UDP glucuronosyltransferase 2 family, polypeptide B17 gene deletion polymorphism, wherein detection of the UDP glucuronosyltransferase 2 family, polypeptide B17gene deletion polymorphism is correlated with altered therapeutic efficacy of the exesmestane in the subject compared to a control subject; and treating the subject with exemestane based on a result of assaying the biological sample where the subject is determined to have no UDP glucuronosyltransferase 2 family, polypeptide B17 gene deletion polymorphism or determining an alternative treatment without exemestane based on a result of assaying the biological sample where the subject is determined to have a UDP glucuronosyltransferase 2 family, polypeptide B17 gene deletion polymorphism.